Skip to content

Clinical Trial to Evaluate the Tolerability and Efficacy of Microencapsulated Calcium Carbonate

Clinical Trial to Evaluate the Gastric Tolerability and Efficacy of the Food Supplement of Microencapsulated Calcium Carbonate vs Conventional Calcium Carbonate and Calcium Citrate

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03452696
Acronym
CALCIMIP
Enrollment
208
Registered
2018-03-02
Start date
2018-06-15
Completion date
2019-04-03
Last updated
2019-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypocalcemia; Dietary

Brief summary

Interventional Clinical trial with food supplement, randomized, double-blind, comparative between microencapsulated calcium, calcium carbonate salts standardized and calcium citrate, in a population of postmenopausal women, lasting 1 month.

Interventions

DIETARY_SUPPLEMENTCalcium supplement

Calcium supplement for low contribution of elemental calcium in the daily diet

Sponsors

Nexentia S.A.S.
CollaboratorUNKNOWN
Instituto Palacios
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Women

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Postmenopausal woman * Low contribution of elemental calcium in the daily diet

Exclusion criteria

* Hypersensitivity to the active substances or to any of the excipients * Renal insufficiency * History of kidney or urinary stones * Use in the last month of diuretics (furosemide, ethacrynic acid), aluminum salts and / or thyroid hormones * Use of any other drug or experimental device during the 30 days prior to the selection

Design outcomes

Primary

MeasureTime frameDescription
Gastric symptoms1 monthUsing the Gastrointestinal Symptom Rating Scale (GRS). The scale measures constipation, diarrhea, windiness, swelling, nausea, reflux, pain and burning. The patient will have to choose the most appropriate response among those proposed. Not at all is the better outcome and very strong discomfort is the worst outcome

Secondary

MeasureTime frameDescription
Changes in bone markersBasal and 1 monthBone Marker Analysis (CTx and P1NP) will be performed

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026